Attached files
| file | filename |
|---|---|
| EX-21.1 - EXHIBIT 21.1 - IMMUNE PHARMACEUTICALS INC | c14837exv21w1.htm |
| EX-31.2 - EXHIBIT 31.2 - IMMUNE PHARMACEUTICALS INC | c14837exv31w2.htm |
| EX-32.2 - EXHIBIT 32.2 - IMMUNE PHARMACEUTICALS INC | c14837exv32w2.htm |
| EX-32.1 - EXHIBIT 32.1 - IMMUNE PHARMACEUTICALS INC | c14837exv32w1.htm |
| EX-31.1 - EXHIBIT 31.1 - IMMUNE PHARMACEUTICALS INC | c14837exv31w1.htm |
| 10-K - FORM 10-K - IMMUNE PHARMACEUTICALS INC | c14837e10vk.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-160571, 333-153895,
333-153256, 333-147589, 333-145561, 333-145133 and 333-132613 on Form S-3 and Registration
Statement Nos. 333-156438, 333-151150, 333-130865, 333-130861and 333-130860 on Form S-8 of our
report dated March 11, 2011, relating to the consolidated financial statements of EpiCept
Corporation and subsidiaries (the “Company”) (which report expresses an unqualified opinion and
includes an explanatory paragraph relating to the Company’s ability to continue as a going concern
as discussed in Note 2 to the consolidated financial statements) appearing in the Annual Report on
Form 10-K of EpiCept Corporation for the year ended December 31, 2010.
/s/ DELOITTE & TOUCHE LLP
Parsippany, New Jersey
March 31, 2011
March 31, 2011